Notice: This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends TORC vs. PEPG, SGMT, IVA, SKYE, TELO, IXHL, MCRB, RPTX, PYXS, and LLYShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include PepGen (PEPG), Sagimet Biosciences (SGMT), Inventiva (IVA), Skye Bioscience (SKYE), Telomir Pharmaceuticals (TELO), Incannex Healthcare (IXHL), Seres Therapeutics (MCRB), Repare Therapeutics (RPTX), Pyxis Oncology (PYXS), and Eli Lilly and Company (LLY). These companies are all part of the "medical" sector. resTORbio vs. PepGen Sagimet Biosciences Inventiva Skye Bioscience Telomir Pharmaceuticals Incannex Healthcare Seres Therapeutics Repare Therapeutics Pyxis Oncology Eli Lilly and Company PepGen (NASDAQ:PEPG) and resTORbio (NASDAQ:TORC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings. Does the media favor PEPG or TORC? In the previous week, PepGen had 5 more articles in the media than resTORbio. MarketBeat recorded 5 mentions for PepGen and 0 mentions for resTORbio. PepGen's average media sentiment score of 0.36 beat resTORbio's score of 0.00 indicating that PepGen is being referred to more favorably in the media. Company Overall Sentiment PepGen Neutral resTORbio Neutral Which has stronger valuation & earnings, PEPG or TORC? PepGen is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$78.63M-$2.98-1.44resTORbioN/AN/A-$82.74M-$2.41-0.40 Do institutionals and insiders believe in PEPG or TORC? 58.0% of PepGen shares are held by institutional investors. Comparatively, 46.2% of resTORbio shares are held by institutional investors. 4.6% of PepGen shares are held by company insiders. Comparatively, 11.8% of resTORbio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PEPG or TORC? resTORbio received 123 more outperform votes than PepGen when rated by MarketBeat users. However, 81.82% of users gave PepGen an outperform vote while only 67.14% of users gave resTORbio an outperform vote. CompanyUnderperformOutperformPepGenOutperform Votes1881.82% Underperform Votes418.18%resTORbioOutperform Votes14167.14% Underperform Votes6932.86% Do analysts rate PEPG or TORC? PepGen currently has a consensus price target of $14.67, suggesting a potential upside of 242.68%. Given PepGen's stronger consensus rating and higher probable upside, equities research analysts plainly believe PepGen is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, PEPG or TORC? PepGen has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, resTORbio has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Is PEPG or TORC more profitable? PepGen's return on equity of -60.17% beat resTORbio's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -60.17% -48.88% resTORbio N/A -78.12%-71.63% SummaryPepGen beats resTORbio on 10 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.26M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-0.535.5095.1214.22Price / SalesN/A375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book0.4310.276.976.37Net Income-$82.74M$153.22M$118.73M$225.56M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.97-5.8%N/A-19.4%$35.26MN/A-0.53N/APEPGPepGen2.466 of 5 stars$4.28-2.7%$14.67+242.7%-5.6%$139.53MN/A0.0072Analyst ForecastSGMTSagimet Biosciences2.1976 of 5 stars$4.52flat$21.60+377.9%+50.2%$138.63M$2M0.008IVAInventiva3.0751 of 5 stars$2.51-8.4%$14.00+457.8%-31.9%$131.73M$18.91M0.00100News CoverageGap DownSKYESkye Bioscience1.2925 of 5 stars$4.28-1.4%$18.67+336.1%+152.9%$129.86MN/A0.0011Insider TradeTELOTelomir PharmaceuticalsN/A$4.38+4.3%N/AN/A$129.69MN/A0.001News CoverageGap UpHigh Trading VolumeIXHLIncannex Healthcare1.3675 of 5 stars$2.03-2.9%N/A+132.2%$128.86M$10,000.000.003MCRBSeres Therapeutics3.6801 of 5 stars$0.75-7.7%$5.08+576.8%-16.1%$128.24M$126.32M0.00233Analyst UpgradeRPTXRepare Therapeutics2.6778 of 5 stars$3.01+6.0%$10.00+232.2%-44.7%$127.96M$51.13M0.00180Gap UpPYXSPyxis Oncology1.2976 of 5 stars$2.13-44.2%$10.00+369.5%+165.3%$126.67MN/A-1.9660Analyst ForecastNews CoverageGap DownHigh Trading VolumeLLYEli Lilly and Company4.9913 of 5 stars$750.87-0.3%$1,007.94+34.2%+26.0%$712.82B$34.12B80.0043,000Analyst Revision Related Companies and Tools Related Companies PepGen Alternatives Sagimet Biosciences Alternatives Inventiva Alternatives Skye Bioscience Alternatives Telomir Pharmaceuticals Alternatives Incannex Healthcare Alternatives Seres Therapeutics Alternatives Repare Therapeutics Alternatives Pyxis Oncology Alternatives Eli Lilly and Company Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TORC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
